Padova

• A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years o … Ended recruitment
  2023-504277-20-00 5 2023-01-30 Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorde
• A clinical study of a virus transferring the gene for human Ornithine Transcarbamylase (OTC) in patients 12 years of age and older with late … Ended recruitment
  2024-514337-38-00 5 2023-01-24 Late-onset Ornithine transcarbamylase (OTC) deficiency
• A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended recruitment
  2022-501744-15-00 5 2023-01-23 Obesity, Overweight
• A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated … Ended recruitment
  2023-504027-78-00 4 2023-01-13 Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
• Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy Ended recruitment
  2022-500090-13-00 4 2022-12-29 Becker Muscular Dystrophy (BMD)
• RESTORING SENSITIVITY TO IMMUNOTHERAPY IN ADVANCED TRIPLE NEGATIVE BREAST CANCER EXPLOITING CERALASERTIB PRIMING FOLLOWED BY COMBINED DURVAL … Ended recruitment
  2024-513721-23-00 4 2022-12-15 ADVANCED TRIPLE NEGATIVE BREAST CANCER
• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U … Ended recruitment
  2023-505772-30-00 5 2022-11-09 Melanoma
• An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) Ended recruitment
  2023-509201-77-00 5 2022-11-02 Hereditary Angioedema
• A research study to see how well CagriSema helps people with excess body weight lose weight Ended recruitment
  2023-506929-11-00 5 2022-10-17 Overweight and obesity
• A safety and pharmacokinetic study of oral berotralstat for HAE attacks in pediatric patients. Ended recruitment
  2024-511257-22-00 5 2022-10-13 Hereditary Angioedema (HAE)
• A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin … Ended recruitment
  2023-503467-41-00 5 2022-10-12 Relapsed or Refractory Multiple Myeloma
• Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended recruitment
  2023-509429-37-00 5 2022-10-03 Advanced or Metastatic Non-Small Cell Lung Cancer
• A randomized, two-armed, single-blind, parallel, active controlled, and non-inferiority clinical trial to Compare Efficacy and Safety of ant … Ended recruitment
  2024-515557-22-00 6 2022-10-01 Juvenile Idiopathic Arthritis
• A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria Ended recruitment
  2023-509229-31-00 5 2022-09-28 Metabolic Disorders - Phenylketonuria
• Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies (FLOTILLA Study) Ended recruitment
  2023-509408-13-00 6 2022-09-20 Solid tumors
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously U … Ended recruitment
  2023-504194-21-00 5 2022-09-13 PD-L1 Positive Metastatic Triple-Negative Breast Cancer
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable … Ended recruitment
  2023-504195-14-00 5 2022-08-31 PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
• A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu … Ended recruitment
  2022-500014-26-00 5 2022-06-24 Locally-Advanced unresectable or Metastatic breast cancer (MBC)
• A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanc … Ended recruitment
  2024-512378-91-00 4 2022-06-24 Unresectable or Advanced Melanoma
• A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cho … Ended recruitment
  2023-505764-11-00 4 2022-06-10 Pruritus associated with Primary Sclerosing Cholangitis (PSC)
• A multicentre phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maint … Ended recruitment
  2024-516157-41-00 4 2022-05-27 Metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC)
• A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small ce … Ended recruitment
  2023-509943-28-00 5 2022-05-18 Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (
• Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA) Ended recruitment
  2023-508536-64-00 9 2022-05-17 Metastatic Prostate Cancer
• Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2) Ended recruitment
  2024-517424-18-00 6 2022-05-10 Patients with EGFR mutant NSCLC according to TP53 mutational status

Showing 505–528 of 769 trials